CenterBook Partners’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,899
Closed -$778K 677
2025
Q4
$778K Sell
3,899
-19,895
-84% -$3.61M 0.04% 415
2025
Q3
$3.72M Buy
23,794
+20,041
+534% +$3.18M 0.18% 153
2025
Q2
$569K Sell
3,753
-10,272
-73% -$1.37M 0.03% 415
2025
Q1
$2.11M Sell
14,025
-11,593
-45% -$1.94M 0.13% 192
2024
Q4
$4.73M Buy
+25,618
New +$4.93M 0.28% 104

Other funds holding CRL

CenterBook Partners's CRL Position: Q1 2026 in Review

CenterBook Partners sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 3,899 shares — an estimated $778K sold.

CenterBook Partners first reported a position in CRL in Q4 2024 and held it in 5 quarters. The position peaked at $4.73M in Q4 2024. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • CenterBook Partners reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • CenterBook Partners sold 3,899 Charles River Laboratories shares in Q1 2026, an estimated $778K.
  • CenterBook Partners first reported a position in Charles River Laboratories in Q4 2024 and held it in 5 quarters.
  • CenterBook Partners's Charles River Laboratories position peaked at $4.73M in Q4 2024.
  • 560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on CenterBook Partners's 13F filing for Q1 2026, filed 5 May 2026.